CAPITAL REPRESENTATIVES' CONFERENCE AND 2024 ANNUAL REVIEW, 2025 PLAN DEPLOYMENT OF VIETNAM PHARMACEUTICAL CORPORATION - JSC ON FEBRUARY 17, 2024

The conference was honored to welcome Mr. Do Xuan Tuyen - Deputy Secretary of the Party Committee, Party Secretary, Standing Vice Minister of Health; Mr. Nguyen Quoc Huy - Board Member and General Director of State Capital Investment Corporation (SCIC); Representatives from various departments of the Ministry of Health; Mr. Trinh Van Lau - Chairman of the Vietnam Pharmaceutical Enterprises Association, along with the attendance of Vinapharm's Board of Directors and Executive Board members; Representatives from companies with Vinapharm's capital investment and 18 Capital Representatives from Vinapharm at 23 enterprises.

At the conference, Ms. Han Thi Khanh Vinh - Board Member and General Director of Vinapharm, reported on the business performance for 2024 and business plans for 2025. In 2024, Vinapharm achieved numerous positive results, exceeding set targets; Vinapharm's profit before tax according to both consolidated and combined financial statements showed double-digit growth. Additionally, Vinapharm completed the transition of its management organizational structure to include an audit committee under the Board of Directors; Reviewed, amended, and issued regulations to further improve corporate governance effectiveness according to the restructuring plan approved by the General Shareholders' Meeting; Continued to strengthen connections, coordination, and support between Vinapharm and its member companies.

In 2024, Vinapharm was honored to receive prestigious awards from respected domestic and regional organizations, recognizing achievements in pharmaceuticals and community contributions: (i) Asia's Excellence Enterprise Award 2024 by Enterprise Asia; (ii) Top 10 Prestigious Pharmaceutical Distribution Companies in the Pharmaceutical & Medical Equipment, Healthcare sector 2024 by Vietnam Report.

For active contributions to developing the Draft Law amending and supplementing certain articles of the Pharmaceutical Law, Vinapharm's General Director was awarded the Minister of Health's Certificate of Merit for outstanding achievements in developing healthcare legislation contributing to public health protection and care. Additionally, Vinapharm's General Director was honored in the Outstanding Asian Entrepreneur 2024 category by Enterprise Asia, recognizing individuals with exceptional achievements in business leadership and management.

Ms. Han Thi Khanh Vinh - Board Member, General Director of Vinapharm presenting the report at the Conference

Regarding the business performance of companies with Vinapharm's capital investment: The majority of enterprises effectively implemented the Shareholders' General Meeting Resolution and business plan targets. Among them, 14/23 enterprises recorded profit growth compared to the previous year and exceeded planned targets; 07/23 enterprises recorded profit before tax exceeding 100 billion VND, including: Sanofi Vietnam JSC, Imexpharm Pharmaceutical JSC, Sanofi Synthelabo Vietnam Pharmaceutical JSC, CPC1 Central Pharmaceutical JSC, TW3 Pharmaceutical JSC, OPC Pharmaceutical JSC, and TW2 Medicinal Materials JSC; 05/23 enterprises contributed the highest dividend revenue: Sanofi Vietnam JSC, CPC1 Central Pharmaceutical JSC, Imexpharm Pharmaceutical JSC, TW3 Pharmaceutical JSC, and OPC Pharmaceutical JSC.

Regarding the 2025 business plan, Vinapharm has set targets for revenue growth of 3% and combined profit before tax growth at double digits (11%) compared to 2024 performance. For companies with Vinapharm's capital investment, 09/21 enterprises have set revenue targets and 04/21 enterprises have set profit before tax targets for 2025 with growth of 8% or higher compared to the previous year.

Regarding the management of Capital Representatives at enterprises with Vinapharm's investment: Generally in 2024, Vinapharm's Capital Representatives at various enterprises have fully complied with legal regulations, enterprise charters, and Vinapharm's Representative Management Regulations. To recognize the enterprises' efforts and commend the Representatives' contributions in 2024, Vinapharm presented certificates of merit to 07 enterprises with outstanding business results and 02 dedicated Representatives who had served as capital representatives for 12 months or more and were evaluated as having successfully fulfilled their duties according to Vinapharm's representative management regulations.

Mr. Do Xuan Tuyen - Standing Vice Minister of Health, Mr. Nguyen Quoc Huy - General Director of SCIC, and Vinapharm's Leadership Team taking commemorative photos with Enterprises and Capital Representatives who successfully completed their 2024 tasks

Mr. Nguyen Quoc Huy - Board Member and General Director of SCIC highly appreciated Vinapharm's business performance and implementation of the restructuring plan in 2024. These results demonstrate the efforts of the Leadership Team and all employees of Vinapharm and its member enterprises. SCIC will continue to support and strengthen connections and cooperation between Vinapharm, its capital-invested enterprises, and other SCIC-invested pharmaceutical companies, as well as support Vinapharm and its member enterprises in seeking, promoting, and expanding international cooperation opportunities, contributing to the development of Vietnam's pharmaceutical industry.

Mr. Nguyen Quoc Huy - Board Member, General Director of SCIC speaking at the Conference

Speaking at the conference, Standing Vice Minister of Health Do Xuan Tuyen acknowledged and highly appreciated Vinapharm's proactive approach in collaborating with the Ministry of Health and the Drug Administration in developing the draft Law amending and supplementing certain articles of the Pharmaceutical Law. In the context where Vietnam's pharmaceutical industry faces many challenges due to the structural shift from chemical drugs to biological and biosimilar pharmaceuticals, along with requirements for digital transformation, green transformation, and sustainable development, Vinapharm and its member enterprises "need to quickly approach and focus on investing in science and technology towards applying modern and high technology, producing new drugs, high-quality medicinal materials, developing national brand herbal medicines, promoting cooperation and technology transfer for patented innovative drugs, specialty therapeutic drugs, and high-tech generic drugs," "continue to strengthen international cooperation," "continue to actively seek opportunities and partners to implement factory construction, receive technology transfer for pharmaceutical, biological, and biosimilar products in Vietnam," "continue to accompany the Ministry of Health and Drug Administration in developing, amending, and supplementing implementation decrees and industry regulatory documents, as well as actively proposing solutions to state management agencies to promptly resolve difficulties and obstacles, creating conditions for pharmaceutical enterprises in particular and Vietnam's pharmaceutical industry in general to develop strongly, healthily and integrate well with the world."

Standing Vice Minister of Health Do Xuan Tuyen speaking at the Conference

In the context of volatile global economics and increasingly complex business environment impacted by factors such as economic recession, geopolitical instability, climate change, technological advancement, and increasingly stringent legal compliance requirements, corporate governance, including risk management, has become a key factor in ensuring sustainable enterprise development. The conference heard insights from Mr. Nguyen The Manh - Advisory Director of Deloitte Southeast Asia, member of the Audit Committee Practice Development Advisory Council - Vietnam Institute of Directors (VIOD) on the topic: "Risk Management linked to Effective Corporate Governance - Capital Representatives' perspective."

Mr. Nguyen The Manh - Advisory Director of Deloitte Southeast Asia, member of the Audit Committee Practice Development Advisory Council - Vietnam Institute of Directors sharing at the Conference

The conference also heard presentations from representatives of enterprises with Vinapharm's capital investment: Sanofi Vietnam Joint Stock Company and CPC1 Central Pharmaceutical Joint Stock Company.

Representatives from Sanofi Vietnam and CPC1 presenting at the Conference

With the direction, attention, and accompaniment of the Ministry of Health, Drug Administration, SCIC, the cooperation, contribution, and sharing of enterprises, Representatives, along with the unity and determination of shareholders, Leadership Team and employees, Vietnam Pharmaceutical Corporation - JSC is confident in achieving the 2025 plan targets with sustainable and effective development goals, striving to contribute more to the development of Vietnam's pharmaceutical industry and the cause of public healthcare, "stepping firmly into an era of growth" alongside the country.

Mr. Dinh Xuan Han - Chairman of Vinapharm's Board of Directors delivering thank you remarks and closing the Conference

Some photos from the Conference